SarcomaTreatment Market, by Sarcoma Type (Soft Tissue Sarcoma, Bone Sarcoma, andOthers), by Treatment Type (Chemotherapy, Targeted Therapy and Others), byDistribution Channel (Hospital Pharmacies, Retail Pharmacies, OnlinePharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019- 2027
Sarcoma is a type of cancer,which occurs in connective tissues. Moreover, sarcoma is broadly classifiedinto two types such as soft tissue sarcoma and bone sarcoma. Soft tissuesarcomas occur in tissues of blood vessels, nerves, tendons, muscles, fat, andlining of the joints. Soft tissue sarcomas are mostly found in legs, arms,abdomen, and chest. There are over 50 types of soft tissue sarcoma. Soft tissuesarcoma symptoms include lump growth, abdominal pain, blood in stools, and vomiting.
Bone sarcomas mostly occur in thelong bones in arms and legs, and the pelvic bones. Symptoms of bone sarcomainclude fatigue, weaken bone leading to frequent fractures, bone pain, andswelling and tenderness near the affected area. On the basis of severity ofcancer, sarcomas are divided into four stages, which include Stage 1 to Stage4. Sarcomas are treated through chemotherapies, radiation therapies, targetedtherapies, and surgeries.
* The sample copy includes: Report Summary, Table of Contents,Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3537
Global Sarcoma Treatment Market –Dynamics
Key players are focusing onenhancing their product portfolio through product launches and new productapprovals for sarcoma treatment, which is expected to boost sarcoma treatmentmarket growth over the forecast period. For instance, in January 2020, Epizyme,Inc., received the U.S. Food and Drug Administration (FDA) approval forTazverik, a target specific drug indicated for the treatment of epithelioidsarcoma in patients of age 16 and above.
Furthermore, players operating inthe market are focused on research for development of new and efficienttreatment for sarcoma, which is expected to propel growth of the market overthe forecast period. For instance, in October 2019, Tyme Technologies, Inc.initiated HopES, a phase 2 clinical trial, to evaluate safety and efficacy ofSM-88, a monotherapy for clinically advanced sarcomas. The trial is expected tocomplete in the year 2022.
Global Sarcoma Treatment Market –Regional Insights
North America accounted for thelargest market share in 2018. This is attributed to rising incidences ofsarcomas in the region. For instance, the American Cancer Society has estimatedthat in 2020, around 13,130 new cases of soft tissue sarcomas will be diagnosedin the U.S. Furthermore, in 2018, the American Cancer Society reported thatrhabdomyosarcoma accounts for around 3% cases of pediatric cancers in the U.S.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/sarcoma-treatment-market-3537
Europe is expected to be thesecond-largest market in global sarcoma treatment market and it is expected towitness significant growth over the forecast period, owing to increasing numberof sarcoma incidences in the region. For instance, in July 2018, Sarcoma UK, anational cancer charity, reported that over 5,300 cases of sarcomas arediagnosed every year in the U.K.
Global Sarcoma Treatment Market –Competitive Landscape
Key players operating in thesarcoma treatment market include Novartis International AG, Eli Lilly andCompany, Amgen Inc., Johnson & Johnson, Johnson & Johnson, Bayer AG,Epizyme, Inc., Tyme Technologies, Inc., and others.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3537
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
